Skip to content

US · FEED · MEDICAL - SPECIALTIES

ENvue Medical, Inc. (FEED) intrinsic value and stock valuation

$1.03as of 2026-11-21 · Mkt cap 413.82K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ENvue Medical, Inc. DCF and intrinsic value

InvestorsCraft values FEED with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FEED’s statements →

ENvue Medical, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Specialties Tyler, TX 77569 envuemed.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.55M+32.7% 5y CAGRd
20112025
Net income
-$-18.18M
20112025
Free cash flow
-$-9.43M
20112025
Total equity
$33.5M+69.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.55M$2.56M$2.28M$750K$1.7M
Operating income-$-11.73M-$-3.58M-$-3.44M-$-5.01M-$-5.68M
Net income-$-18.18M-$-3.71M-$-3.71M-$-5.45M-$-14.28M
EPSd-$-21.14M-$-123.67M-$-185.5M-$-545M-$-1.43B
Operating cash flow-$-9.37M-$-2.52M-$-3.6M-$-7.04M-$-4.37M
Capital expenditure-$-60K-$0.00-$0.00-$0.00-$0.00
Free cash flow-$-9.43M-$-2.52M-$-3.6M-$-7.04M-$-4.37M
Total assets$41.1M$3.63M$6.67M$5.88M$8.62M
Total debt$1.2M$120K$10K$80K$50K
Net debt-$-3.03M-$-640K-$-3.28M-$-2.63M-$-7.69M
Total equity$33.5M$630K$3.99M$3.23M$6.31M
Cash and short-term investments$4.22M$750K$3.28M$2.71M$7.74M
Income statement
20252024202320222021
Revenue$2.55M$2.56M$2.28M$750K$1.7M
Cost of revenue$2.4M$1.05M$750K$580K$930K
Gross profit$150K$1.51M$1.54M$170K$770K
Research and development expenses$1.76M$910K$180K$280K$290K
Selling, general and administrative expenses$10.1M$4.18M$4.79M$4.9M$6.16M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$11.9M$5.09M$4.97M$5.18M$6.45M
Cost and expenses$14.3M$6.14M$5.72M$5.76M$7.38M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$290K$140K$250K$350K$0.00
Depreciation and amortization$900K$0.00$0.00$0.00$0.00
Ebitda-$-17.59M-$-3.69M-$-3.55M-$-5.41M-$-14.25M
Operating income-$-11.73M-$-3.58M-$-3.44M-$-5.01M-$-5.68M
Total other income/expenses, net-$-6.76M-$-100K-$-250K-$-400K-$-8.57M
Income before tax-$-18.49M-$-3.69M-$-3.68M-$-5.41M-$-14.25M
Income tax expense-$-310K$20K$30K$40K$30K
Net income-$-18.18M-$-3.71M-$-3.71M-$-5.45M-$-14.28M
Weighted average shares outstanding$860K$30K$20K$10K$10K
Weighted average diluted shares outstanding$860K$30K$20K$10K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$4.22M$750K$3.28M$2.71M$7.74M
Net receivables$540K$270K$420K$110K$260K
Inventory$2.34M$2.19M$2.73M$2.17M$170K
Total current assets$7.27M$3.33M$6.49M$5.61M$8.34M
Property, plant and equipment, net$250K$120K$10K$90K$50K
Goodwill and intangible assets$33.5M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$33.9M$300K$190K$270K$280K
Total assets$41.1M$3.63M$6.67M$5.88M$8.62M
Accounts payable$720K$50K$140K$70K$90K
Short-term debt$1.17M$50K$10K$80K$50K
Deferred revenue$170K$10K$50K$20K$40K
Total current liabilities$6.66M$2.72M$2.45M$2.32M$1.9M
Long-term debt$30K$60K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$10K$110K$150K
Total non-current liabilities$970K$280K$230K$330K$410K
Capital lease obligations$120K$60K$0.00$0.00$0.00
Total liabilities$7.63M$3M$2.69M$2.65M$2.31M
Common stock$0.00$0.00$0.00$0.00$30K
Retained earnings-$-90.48M-$-69.8M-$-66.1M-$-62.38M-$-56.94M
Accumulated other comprehensive income (loss)-$-80K-$-80K-$-70K-$-20K$60K
Total equity$33.5M$630K$3.99M$3.23M$6.31M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.2M$120K$10K$80K$50K
Net debt-$-3.03M-$-640K-$-3.28M-$-2.63M-$-7.69M
Cash flow statement
20252024202320222021
Net income-$-18.18M-$-3.71M-$-3.71M-$-5.45M-$-14.28M
Depreciation and amortization$900K$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$360K$290K$350K$380K
Change in working capital$1.66M$730K-$-320K-$-2.31M-$-490K
Accounts receivable-$-280K$220K-$-310K$190K-$-170K
Inventory$250K$540K-$-560K-$-2M-$-30K
Accounts payable$550K$150K$50K$60K-$-320K
Net cash provided by operating activities-$-9.37M-$-2.52M-$-3.6M-$-7.04M-$-4.37M
Investments in property, plant and equipment-$-60K-$0.00-$0.00-$0.00-$0.00
Acquisitions, net$150K$0.00$0.00$0.00$0.00
Net cash used for investing activities$90K-$0.00-$0.00-$0.00-$0.00
Common stock issued$19.2M$0.00$4.22M$2.09M$4.97M
Common stock repurchased-$-5M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.8M$0.00$4.22M$2.09M$4.58M
Net change in cash$3.5M-$-2.53M$570K-$-5.02M$200K
Cash at end of period$4.25M$750K$3.28M$2.71M$7.74M
Operating cash flow-$-9.37M-$-2.52M-$-3.6M-$-7.04M-$-4.37M
Capital expenditure-$-60K-$0.00-$0.00-$0.00-$0.00
Free cash flow-$-9.43M-$-2.52M-$-3.6M-$-7.04M-$-4.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ENvue Medical, Inc.

        NanoVibronix, Inc. focuses on developing non-surgical medical devices that stimulate biological responses. Its core offerings include UroShield and PainShield. The company's business activities span across several global markets, such as the United States, Europe, Australia, India, and Israel, in addition to other territories. This enterprise was founded by Harold Jacob and Jona Zumeris in September 2003, and its main corporate office is situated in Tyler, Texas.

        CEO
        Doron Robert Besser
        Employees
        14
        Beta
        1.56

        Explore

        Frequently asked questions

        What is the intrinsic value of ENvue Medical, Inc. (FEED)?

        InvestorsCraft does not currently publish an intrinsic value for FEED. How the IC value is calculated.

        Is FEED undervalued?

        InvestorsCraft does not publish an undervaluation signal for FEED at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.